Literature DB >> 932225

Conditions for collection of serum samples for the measurement of fibrin(ogen) degradation products by radioimmunoassay of fragment E.

M J Martin, Y B Gordon, S M Ratky, L R Baker, T Chard.   

Abstract

A number of conditions have been assessed for the collection of serum samples for the measurement of fibrin(ogen) degradation products using a radioimmunoassay for degradation fragment E, which permits precise quantitation of differences. Blood should be collected using minimal venous occlusion into glass tubes containing 10 mg/ml of epsilon amino caproic acid and allowed to clot at 4 to 20 degrees C for at least 4 hours before centrifugation. The serum may be stored at 4 or -20 degrees C. Samples from patients receiving anticoagulant therapy should be treated with 10 IU of thrombin per ml.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 932225      PMCID: PMC476058          DOI: 10.1136/jcp.29.4.336

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  The influence of beta-adrenergic blockade upon baseline blood coagulation and fibrinolytic activity and upon the responses to venous occlusion.

Authors:  M J Butler; M Smith; M H Irving; Y B Gordon; S M Ratky; J W Rivers; C Hawkey
Journal:  Thromb Diath Haemorrh       Date:  1975-09-30

2.  DEMONSTRATION OF FIBRINOLYTIC SPLIT PRODUCTS IN HUMAN SERUM BY AN IMMUNOLOGICAL METHOD IN SPONTANEOUS AND INDUCED FIBRINOLYTIC STATES.

Authors:  J E NILEHN; I M NILSSON
Journal:  Scand J Haematol       Date:  1964

3.  [Free fibrin in the circulation. Immunological test for the identification of free fibrin].

Authors:  H C FERREIRA; L G MURAT
Journal:  Rev Paul Med       Date:  1961-08

4.  High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization.

Authors:  V J Marder; N R Shulman; W R Carroll
Journal:  J Biol Chem       Date:  1969-04-25       Impact factor: 5.157

5.  Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay.

Authors:  Y B Gordon; M J Martin; A T McNeile; T Chard
Journal:  Lancet       Date:  1973-11-24       Impact factor: 79.321

6.  Serum fibrin-fibrinogen degradation products in acute myocardial infarction.

Authors:  L O Almer; U Hedner; I M Nilsson
Journal:  Lancet       Date:  1972-04-29       Impact factor: 79.321

7.  Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo.

Authors:  E Plow; T S Edgington
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

8.  Degradation of fibrinogen by proteolytic enzymes.

Authors:  Z S Latallo; E Teisseyre; Z Wegrzynowicz; M Kopéc
Journal:  Scand J Haematol Suppl       Date:  1971

9.  Intravascular coagulation during pregnancy and the puerperium.

Authors:  E Hyde; D Joyce; V Gurewich; P T Flute; S Barrera
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-12

10.  Plasma fibrinogen and its fragments during streptokinase treatment.

Authors:  P J Gaffney; C N Chesterman; M J Allington
Journal:  Br J Haematol       Date:  1974-02       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.